<DOC>
	<DOCNO>NCT01512849</DOCNO>
	<brief_summary>The purpose study evaluate PK/PD safety TA-7284 patient type 2 diabetes mellitus moderate renal impairment .</brief_summary>
	<brief_title>A Study Evaluate PK/PD Safety TA-7284 Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment</brief_title>
	<detailed_description>This open-label , randomize , 2-way crossover study evaluate PK/PD safety TA-7284 patient type 2 diabetes mellitus moderate renal impairment relative patient type 2 diabetes mellitus normal renal function . The patient receive TA-7284-Low TA-7284-High orally alone either Period 1 2 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Patients type 2 diabetes mellitus stable condition normal renal function moderate renal impairment Body mass index ≥18.5 kg/m2 ≤39.9 kg/m2 screen HbA1c ≥6.5 % ≤10.5 % screen Type 1 diabetes mellitus , diabetes mellitus result pancreatic disorder , secondary diabetes mellitus Past current history severe diabetic complication Patients require insulin therapy History hereditary glucosegalactose malabsorption primary renal glucosuria</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TA-7284</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Renal Impairment</keyword>
	<keyword>Sodium Glucose Co-transporter2 ( SGLT2 ) inhibitor</keyword>
</DOC>